The therapeutic community is abuzz with anticipation surrounding retatrutide, a novel dual GIP and GLP-1 target that’s exhibiting significant potential in clinical trials for addressing obesity. Unlike some existing weight loss treatments, retatrutide appears to deliver a significant substantial loss in body mass and benefit metabolic function, p